Clinical trial
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving…
NCT00083759 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00083759 |
|---|---|
| Title | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate |
| Official title | A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX) |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | natalizumab, placebo |
| Enrollment | 299 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2005 |
| First posted | Jun 3, 2004 |
| Last update posted | Jul 18, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: